ライフサイエンスコーパス: vasopressin V2 receptor

1 cause of its lack of agonist activity at the vasopressin V2 receptor.

2 and beta2-adrenergic receptors, but not the vasopressin (V2) receptor.

3 iven fluid secretion (PDE3), and response to vasopressin V2 receptor activation (both).

4 than the mixed vasopressin type 1a receptor/vasopressin V2 receptor agonist arginine vasopressin bec

5 treatment of selepressin with the selective vasopressin V2 receptor agonist desmopressin were simila

6 This study sought to examine the effects of vasopressin V2 receptor antagonism with tolvaptan on the

7 Utilizing this protocol, the vasopressin V2 receptor antagonist precursor has been sy

8 d effects were blocked by treatment with the vasopressin V2 receptor antagonist SR121463B, but not by

9 mice before and after administration of the vasopressin V2 receptor antagonist tolvaptan.

10 aptan (OPC-41061), a novel, oral, nonpeptide vasopressin V2-receptor antagonist in patients with chro

11 he effect of long-term administration of the vasopressin V2-receptor antagonist tolvaptan (30 mg/day)

12 atinine clearance, >/=60 ml per minute), the vasopressin V2-receptor antagonist tolvaptan slowed the

13 Tolvaptan, an oral, nonpeptide, selective vasopressin V2-receptor antagonist, shows promise in thi

14 ypervolemic hyponatremia, tolvaptan, an oral vasopressin V2-receptor antagonist, was effective in inc

15 hanistic implications on the emerging use of vasopressin V2 receptor antagonists such as tolvaptan as

16 inhibition of renal intracellular cAMP using vasopressin V2 receptor antagonists, and somatostatin an

17 Vaptans acting on the vasopressin V2 receptors (aquaretics) have attracted att

18 Vasopressin V2 receptor (AVPR2) mRNA was decreased 3 hou

19 isease caused most often by mutations in the vasopressin V2 receptor (AVPR2).

20 One group of nephrotic rats received a vasopressin V2 receptor blocker (V2X) from 4 to 16 wk af

21 Tolvaptan, a vasopressin V2 receptor blocker, shows promise for manag

22 vated betaarr1 upon its interaction with the vasopressin V2 receptor C-terminal phosphopeptide (V2Rpp

23 The data support roles for multiple vasopressin V2-receptor-dependent signaling pathways in

24 circulating vasopressin and up-regulation of vasopressin V2 receptors in ADPKD.

25 Functional engagement of vasopressin V2 receptors is reported to produce rises in

26 We conclude that vasopressin V2 receptors mediate the antidiuretic effect

27 Arginine-vasopressin (AVP) binding to vasopressin V2 receptors promotes redistribution of the

28 eamino-(8-D-arginine)-vasopressin (dDAVP), a vasopressin V2 receptor-selective agonist, for 7 d into

29 unctional, shortened, "diabetic" form of the vasopressin V2 receptor that is the product of incomplet

30 asopressin (AVP) affects kidney function via vasopressin V2 receptors that are linked to activation o

31 II type 1A receptor, neurotensin receptor 1, vasopressin V2 receptor, thyrotropin-releasing hormone r

32 ere we show that co-targeting two GPCRs, the vasopressin V2 receptor (V2R) and the calcium sensing re

33 After agonist-induced internalization, the vasopressin V2 receptor (V2R) does not recycle to the pl

34 The seven-transmembrane-spanning vasopressin V2 receptor (V2R) is a Gs-coupled receptor t

35 to recycle and resensitize rapidly, and the vasopressin V2 receptor (V2R), known to recycle and rese

36 OPC-31260, a vasopressin V2 receptor (VPV2) antagonist, was shown to

37 The vasopressin V2 receptor (VPV2R) antagonist OPC31260 has

38 ous to the human disorders to test whether a vasopressin V2 receptor (VPV2R) antagonist, OPC31260, wo

39 beta2-adrenergic, angiotensin II type 1 and vasopressin V2 receptors was altered by the beta-arresti

40 -7 cells, we found that angiotensin AT1a and vasopressin V2 receptors, which form stable receptor-bet